Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company’s Commercial Performance and Growth Prospects for its Two Core Drug Products

Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the “Class Period”). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis.

Why Was Ardelyx Sued?

According to the complaint, during the Class Period, defendants provided investors with material information concerning Ardelyx’s fiscal year 2026 revenue outlook for its two core drug products, XPHOZAH and IBSRELA, as well as their anticipated long-term growth. Defendants’ statements included, among other things, confidence in the Company’s continued commercial growth and ability to execute its commercial strategy to overcome payer and patient-access barriers, and its ability to achieve its projected revenue guidance and long-term growth targets.

Plaintiff alleges that defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. Plaintiff contends that these statements caused them and other shareholders to purchase Ardelyx’s securities at artificially inflated prices.

Why Did Ardelyx Stock Drop?

On August 6, 2026, Ardelyx announced a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections. On this news, the price of Ardelyx’s common stock fell from a closing market price of $4.87 per share on August 6, 2026, to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.

Who May Be Eligible to Participate in the Ardelyx Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Ardelyx, Inc. securities between January 13, 2025 and August 6, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws. Submit a form for information.

Attorney Advertising. Past results do not guarantee a similar outcome.